


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61N 1/39	A1	(11) International Publication Number: WO 94/00193 (43) International Publication Date: 6 January 1994 (06.01.94)
(21) International Application Number: PCT/US93/03249 (22) International Filing Date: 7 April 1993 (07.04.93) (30) Priority data: 07/864,789 7 April 1992 (07.04.92) US 07/910,611 8 July 1992 (08.07.92) US 07/953,485 29 September 1992 (29.09.92) US 08/033,632 15 March 1993 (15.03.93) US (71) Applicant: ANGEMED, INC. [US/US]; 3650 Annapolis Lane, Minneapolis, MN 55447-5434 (US). (71)(72) Applicants and Inventors: ANDERSON, Kenneth, M. [US/US]; 9125 West Bush Lake Road, Bloomington, MN 55438 (US). SMITH, Charles, U. [US/US]; 10108 Windsor Lake Lane, Minnetonka, MN 55343 (US).		(72) Inventors: KROLL, Mark, W. ; 13011 Brenwood Trail, Minnetonka, MN 55343 (US). ADAMS, Theodore, P. ; 4202 Sunnyside Road, Edina, MN 55435 (US). (74) Agents: KEOUGH, Steven, J. et al.; Patterson & Keough, 1200 Rand Tower, 527 Marquette Avenue South, Minneapolis, MN 55402 (US). (81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR HAVING A SMALLER DISPLACEMENT VOLUME		
		
(57) Abstract <p>A capacitor-discharge implantable cardioverter defibrillator (ICD) has a relatively smaller displacement volume of less than about 90cc. The smaller volume of the ICD is achieved by selecting and arranging the internal components of the ICD to deliver a maximum defibrillation countershock optimized in terms of a minimum physiologically effective current (I_{pe}), rather than a minimum defibrillation threshold energy (DFT). As a result of the optimization in terms of a minimum effective current I_{pe}, there is a significant decrease in the maximum electrical charge energy (E_c) that must be stored by the capacitor of the ICD to less than about 30 Joules, even though a higher safety margin is provided for by the device. Due to this decrease in the maximum E_c, as well as corollary decreases in the effective capacitance value required for the capacitor and the net energy storage required of the battery, the overall displacement volume of the ICD is reduced to the point where subcutaneous implantation of the device in the pectoral region of human patients is practical. The size of the capacitor is reduced because the effective capacitance required can be less than about 125 μF. By optimizing both the charging time and the countershock duration for the smaller maximum E_c, the size of the battery is reduced because the total energy storage capacity can be less than about 1.0 Amp-hours. In the preferred embodiment, the charging time for each defibrillation countershock is reduced to less than about 10 seconds and the pulse duration of the countershock is reduced to less than about 6 milliseconds.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

5

10

**IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
HAVING A SMALLER DISPLACEMENT VOLUME**

TECHNICAL FIELD

The present invention relates generally to the field of automatic,
15 implantable cardioverters and defibrillators. More particularly, the
present invention relates to an implantable cardioverter defibrillator (ICD)
that is a capacitor-discharge device having its internal components,
including a battery and a capacitor, selected and arranged in such a manner
that the ICD has a relatively smaller displacement volume that permits
20 effective subcutaneous implantation of the device in the pectoral region of
human patients.

BACKGROUND OF THE INVENTION

Existing implantable cardioverter defibrillators (ICDs) are typified by
25 a relatively large size that usually requires implantation of the prosthetic
device in the abdominal cavity of a human patient. In order to allow for
effective subcutaneous implantation of a prosthetic device in the pectoral
region of a human patient, the maximum size of the prosthetic device
needs to be less than about 40-90cc, depending upon the physical size and
30 weight of the patient. Unfortunately, all existing ICDs have total
displacement volumes of at least 110cc or greater. Even though there are
numerous advantages to developing an ICD having a displacement
volume small enough to permit implantation of the device in the pectoral

region of a human patient, to date it has been difficult to develop a practical ICD having a total displacement volume of less than about 100cc.

For reasons of simplicity and compactness, existing ICDs are universally capacitor-discharge systems that generate high energy cardioversion/defibrillation countershocks by using a low voltage battery to charge a capacitor over a relatively long time period (i.e., seconds) with the required energy for the defibrillation countershock. Once charged, the capacitor is then discharged for a relatively short, truncated time period (i.e., milliseconds) at a relatively high discharge voltage to create the defibrillation countershock that is delivered through implantable electrode leads to the heart muscle of the human patient.

One of the primary reasons why capacitor-discharge ICDs of a smaller volume have not been developed to date relates to the electrical requirements for storing the high energy cardioversion/defibrillation countershocks that are currently used to defibrillate human patients. Cardioversion countershocks have delivered energies of between about 0.5 to 5.0 Joules and are used to correct detected arrhythmias, such as tachycardia, before the onset of fibrillation. Defibrillation countershocks, on the other hand, have delivered energies greater than about 3.0 Joules and are used to correct ventricular fibrillation or an advanced arrhythmia condition that has not responded to cardioversion therapy.

Presently, all capacitor-discharge ICDs are designed such that the capacitor can store a maximum electrical charge energy of at least about 35 Joules. In contrast, implantable pacemakers, which currently have displacement volumes of less than 50cc, are designed to deliver pacing pulses of no more than about 50 μ Joules. The requirement that a capacitor-discharge ICD be capable of storing an electrical charge with enough energy to deliver an electrical pulse almost one million times as large as that of an implantable pacemaker significantly increases the size of the ICD over the size of the pacemaker due to the size of the electrical components necessary to store this amount of electrical charge energy.

The accepted requirement that ICDs be capable of storing a

maximum electrical charge energy of at least about 35 Joules arises out of the definition of an appropriate safety margin for the device according to a clinically developed defibrillation success curve as shown in Fig. 11. The defibrillation success curve plots the percentage probability of successful
5 defibrillation for a ventricular fibrillation of about 5-10 seconds versus the energy of a monophasic defibrillation countershock as measured in Joules. The safety margin for a given device for a given patient is presently accepted to be the difference between the maximum electrical charge energy (E_c) stored by the capacitor in that device and the median
10 defibrillation threshold energy (DFT) required for that patient.

Under existing medical practice, each time an ICD is implanted in a human patient, an intraoperative testing procedure is attempted in order to determine the median DFT for that patient for the particular electrode lead combination which has been implanted in the patient. The
15 intraoperative testing procedure involves inducing ventricular fibrillation in the heart and then immediately delivering a defibrillation countershock through the implanted electrode leads of a specified initial threshold energy, for example, 20 Joules for a monophasic countershock. If defibrillation is successful, a recovery period is provided for the patient
20 and the procedure is usually repeated a small number of times using successively lower threshold energies until the defibrillation countershock is not successful or the threshold energy is lower than about 10 Joules. If defibrillation is not successful, subsequent countershocks of 35 Joules or more are immediately delivered to resuscitate the patient. After a
25 recovery period, the procedure is repeated using a higher initial threshold energy, for example, 25 Joules. It is also possible that during the recovery period prior to attempting a higher initial threshold energy, the electrophysiologist may attempt to lower the DFT for that patient by moving or changing the electrode leads.

30 The intraoperative testing procedure is designed to accomplish a number of objectives, including patient screening and establishing a minimum DFT for that patient. Typically, if more than 30-35 Joules are

required for successful defibrillation with a monophasic countershock, the patient is not considered to be a good candidate for an ICD. Otherwise, the lowest energy countershock that results in successful defibrillation is considered to be the median DFT for that patient. The use of the lowest
5 energy possible for a defibrillation countershock is premised on the accepted guideline that a countershock which can defibrillate at a lower energy decreases the likelihood of damage to the myocardial tissue of the heart. For a background on current intraoperative testing procedures, reference is made to M. Block, et al., "Intraoperative Testing for
10 Defibrillator Implantation", Chpt. 3; and J.M. Almendral, et al., "Intraoperative Testing for Defibrillator Implantation", Chpt. 4, Practical Aspects of Staged Therapy Defibrillators, edited by Kappenberger, L.J. and Lindemans, F.W., Futura Publ. Inc., Mount Kisco, N.Y. (1992), pgs. 11-21.

Once the median DFT for a patient is established, the
15 electrophysiologist will determine a safety margin for a given ICD device usually by subtracting the median DFT from the maximum E_c stored by that device. Alternatively, a different calculation for the safety margin is sometimes determined by estimating that point on the defibrillation success curve where the electrical energy of a defibrillation countershock
20 will insure a 99% success (E_{99}). Under either definition, the safety margin needs to be large enough to accommodate upward deviations along the defibrillation success curve. Such deviations may be expected, for example, with subsequent rescue defibrillation countershocks delivered later in a treatment after initial cardioversion or defibrillation
25 countershocks of lesser energies were not successful. In these situations clinical data has found that, when delivered after 30 to 40 seconds of ventricular fibrillation, the electrical energy necessary to achieve effective defibrillation may increase 50% or more over the median DFT. As a result, an electrophysiologist usually will require that a given ICD have a
30 first type of safety margin that is typically a factor of at least 2 to 2.5 times the median DFT for that patient before the electrophysiologist will consider implanting the given ICD in that patient. For the alternate E_{99}

point safety margin, the electrophysiologist will require that a given ICD have a maximum E_c at least 10 Joules above the E_{99} point.

Based on current clinical data that the average median DFT is somewhere between 10-20 Joules for a monophasic countershock, the lower limit for the maximum E_c that must be stored by the ICD is accepted to be at least about 35 Joules, and more typically about 39 Joules, in order to generate a maximum defibrillation countershock having an adequate safety margin. The accepted lower limit for the maximum E_c of at least 35 Joules is supported by clinical evaluations, such as Echt, D.S., et al., "Clinical Experience, Complications, and Survival in 70 Patients with the Automatic Implantable Cardioverter/Defibrillator", Circulation, Vol. 71, No. 2:289-296, Feb. 1985. In this article, the authors evaluated data for early AICD devices having maximum E_c energies of 32 Joules stored in a 120 μ F capacitor with a discharge voltage V_d of 750 Volts. In analyzing the clinical data for minimum DFTs, the authors concluded that the 32 Joule device had insufficient energy for effective defibrillation. It should be noted that in the next generation of the particular AICD devices studied, the maximum E_c for the device (the CPI Ventak®) was increased to 39.4 Joules by increasing the capacitance value of the ICD by using a 140 μ F capacitor.

Unfortunately, the requirement that an ICD be capable of storing a maximum E_c of this magnitude effectively dictates that the size of the ICD be greater than about 100cc. This relationship between the maximum E_c that is required for an ICD and the overall size of the ICD can be understood by examining how an ICD stores the electrical energy necessary to deliver a maximum defibrillation countershock.

The only two components that impact on the ability of a capacitor-discharge ICD to store a maximum E_c are the capacitor and the battery, which together occupy more than 60% of the total displacement volume of existing ICDs. Thus, it will be apparent that the size of a capacitor-discharge ICD is primarily a function of the size of the capacitor and the size of the battery. For a capacitor, the physical size of that capacitor is principally determined by its capacitance and voltage ratings. The higher

the capacitance value, the larger the capacitor. Similarly, the physical size of a battery is also principally determined by its total energy storage, as expressed in terms of Amp-hours, for example. Again, the higher the Amp-hours, the larger the battery. With these concepts in mind, it is possible to evaluate how a maximum E_c affects the size of the capacitor and the size of the battery in an ICD.

The maximum electrical charge energy (E_c) of an ICD is usually defined in terms of the capacitance value (C) of the capacitor that stores the charge and the discharge voltage (V_d) at which the electrical charge is delivered as defined by the equation:

$$E_c = 0.5 * C * V_d^2 \quad (\text{Eq. 1})$$

The maximum electrical charge energy (E_c) can also be defined in terms of how the energy is transferred from the battery to the capacitor. In this case, E_c is determined by the charging efficiency (e_c) of the circuitry charging the capacitor, the battery voltage (V_b), the battery current (I_b) and the charging time (t_c) as defined by the equation:

$$E_c = e_c * V_b * I_b * t_c \quad (\text{Eq. 2})$$

When Eqs. 1 and 2 are used to calculate a maximum E_c to be stored by the device, the capacitance value (C) and the charging time (t_c) end up being the only true variables in these equations because the remaining values are all effectively determined by other constraints. In Eq. 1, for example, the discharge voltage (V_d) for present ICDs can be no more than about 800 Volts due to voltage breakdown limitations of high power microelectronic switching components. As a result, V_d is typically between 650-750 Volts. In Eq. 2, it will be found that, for batteries suitable for use in an ICD, the maximum battery output voltage (V_b) for ICDs is typically less than 6 Volts and, due to internal impedances within these batteries, the maximum battery current (I_b) is about 1 Amp. In addition, the charging efficiencies (e_c) of existing ICDs are presently on the order of about 50%.

When Eqs. 1 and 2 are evaluated for any given maximum E_c , it will be found that there necessarily is a minimum capacitance value (C_{min}) for

the capacitor and a minimum charging time (t_{\min}) required to store that maximum E_c in the capacitor of the ICD. Knowing E_c and V_d , Eq. 1 can be reworked as follows to solve for C_{\min} :

$$\begin{aligned} C_{\min} &= 2E_c / V_d^2 & (\text{Eq. 3}) \\ &= 2 * 35 \text{ Joules} / (750 \text{ Volts})^2 \\ &= 124.4 \mu\text{F} \end{aligned}$$

Similarly, knowing E_c , V_b , I_b , and e , Eq. 2 can be reworked as follows to solve for t_{\min} :

$$\begin{aligned} t_{\min} &= E_c / (e * V_b * I_b) & (\text{Eq. 4}) \\ &= (35 \text{ Joules}) / ((0.50) * (6 \text{ Volts}) * (1 \text{ Amp})) \\ &= 12 \text{ seconds} \end{aligned}$$

In other words, the fact that all ICDs presently use a maximum E_c of at least 35 Joules means that all existing ICDs will require capacitors of greater than 124 μF , and that all existing ICDs which draw 1 Amp of current from the battery will have a charging time of greater than 12 seconds. Because the physical size of the capacitor is directly proportional to the capacitance rating of the capacitor in farads for a fixed voltage, the requirement that the capacitor be at least 124 μF is effectively a minimum size limitation on the capacitor for discharge voltages of less than about 800 Volts. Similarly, the requirement that each charging time for a defibrillation countershock draw at least 12 Amp-seconds of current from the battery is also a constructive minimum size limitation on the battery. Thus, it can be seen that the existing requirement for a maximum E_c of at least about 35 Joules effectively dictates the size of both the capacitor and the battery and, consequently, the size of the ICD.

While existing ICDs have been successful in defibrillating human patients, and thereby saving lives, these devices are primarily limited to implantation in the abdominal cavity due to their relatively large size of greater than 110cc. It has long been recognized that it would be advantageous to reduce the total displacement volume of an ICD sufficiently to allow for subcutaneous implantation of the device in the pectoral region of human patients. This can only be done, however, so

long as the device provides for a sufficient safety margin to insure its effectiveness. Accordingly, it would be desirable to provide for an arrangement and configuration of the internal components of a capacitor-discharge ICD such that the total displacement volume of the ICD is reduced, while a sufficient safety margin for the device is retained.

SUMMARY OF THE INVENTION

The present invention is a capacitor-discharge implantable cardioverter defibrillator (ICD) having a relatively smaller displacement volume of less than about 90cc that permits effective subcutaneous implantation of the device in the pectoral region of human patients. The smaller volume of the ICD of the present invention is achieved by selecting and arranging the internal components of the capacitor-discharge ICD in such a manner that the ICD delivers a maximum defibrillation countershock optimized in terms of a minimum physiologically effective current (I_{pe}), rather than a minimum defibrillation threshold energy (DFT). One of the important results of optimizing the maximum defibrillation countershock in terms of a minimum effective current I_{pe} is that there is a significant decrease in the maximum electrical charge energy (E_c) that must be stored by the capacitor of the ICD to less than about 30 Joules, even though a higher safety margin is provided for by the ICD. Due to this decrease in the maximum E_c , as well as corollary decreases in the effective capacitance value required for the capacitor and the net energy storage required of the battery, the overall displacement volume of the ICD of the present invention is reduced to the point where subcutaneous implantation of the device in the pectoral region of human patients is practical.

By using a physiologically effective current (I_{pe}) to determine what is a safe and effective maximum defibrillation countershock, the present invention takes advantages of the realization that it is the effective current delivered to the heart by the defibrillation countershock, and not the total energy of the defibrillation countershock, that results in effective

defibrillation. In other words, the present invention recognizes that all Joules are not created equal and that the cells in the heart muscle will make more effective use of some types of electrical energy and less effective use of other types of electrical energy. The prior art technique of using a minimum DFT energy of the defibrillation countershock to establish safety margins effectively ignores the accepted fact that defibrillation countershock waveforms which differ in shape, tilt and duration, for example, can have significantly different defibrillation threshold energies. In contrast, the effective current I_{pe} as used by the present invention automatically compensates for any differences in the effectiveness of different waveforms. Consequently, the ICD of the present invention uses a minimum effective current I_{pe} delivered to the heart muscle, rather than using a minimum DFT energy, as the measure for insuring an adequate safety margin for the device.

In accordance with a first aspect of the present invention, an implantable cardioverter defibrillator for subcutaneous positioning within a human patient comprises: a sealed housing structure constructed of a biocompatible material and having a displacement volume of less than about 90cc; one or more connector port means, each connector port means disposed in a wall of said housing structure for providing electrical connections between an interior space of said housing structure and a corresponding electrode lead within said human patient; circuit means disposed within said interior space of said housing structure and operably connected to said connector port means for sensing cardiac signals received from one or more of said electrode leads and, in response to the detection of an arrhythmia in said cardiac signals, controlling delivery of one or more high energy electrical cardioversion/defibrillation countershocks of at least 0.5 Joules to the myocardium of said human patient; capacitor means disposed within said interior space of said housing structure and operably connected to said circuit means for storing electrical energy to generate said electrical cardioversion/ defibrillation countershocks and having an effective capacitance value of less than

120 μ F; and battery means disposed within said interior space of said housing structure and operably connected to said circuit means and said capacitor means for providing electrical energy to said circuit means and said capacitor means, wherein said battery means and said capacitor means
5 are selected such that a maximum electrical charge energy stored by said capacitor means for each of said electrical cardioversion/defibrillation countershocks is less than about 30J and said implantable cardioverter defibrillator is capable of delivering at least five of said electrical cardioversion/defibrillation countershocks in a four minute period.

10 In accordance with a second of the present invention, the same elements as the first aspect are recited wherein said battery means and said capacitor means are selected to maximize a physiologically effective current (I_{pe}) for a maximum electrical charge energy (E_c) stored by said capacitor means.

15 In accordance with a third aspect of the present invention, an implantable cardioverter defibrillator for subcutaneous positioning within the pectoral region of a human patient comprises: a sealed housing structure constructed of a biocompatible material and having a displacement volume of less than about 90cc and including one or more
20 connector ports disposed in a wall of said structure for providing electrical connections between an interior space of said structure and electrode leads in said patient; circuit means within said interior space for sensing cardiac signals received from said electrode leads and, in response to the detection of an arrhythmia in said cardiac signals, controlling delivery of one or
25 more electrical cardioversion/defibrillation countershocks of at least 0.5 Joules to said patient; capacitor means within said interior space for storing electrical energy to generate said electrical cardioversion/defibrillation countershocks and having an effective capacitance of less than about 120 μ F; and battery means within said interior space for
30 providing electrical energy to said circuit means and said capacitor means and capable of charging said capacitor means in less than about 10 seconds to a maximum electrical charge energy of less than about 30 Joules.

In accordance with a fourth aspect of the present invention, an implantable cardioverter defibrillator for subcutaneous positioning within the pectoral region of a human patient having electrical energy storage requirements selected so as to treat mild cardiac dysrhythmia conditions comprises: a sealed housing structure constructed of a biocompatible material and having a displacement volume of less than about 50cc and including one or more connector ports disposed in a wall of said structure for providing electrical connections between an interior space of said structure and electrode leads in said patient; circuit means within said interior space for sensing cardiac signals received from said electrode leads and, in response to the detection of an arrhythmia in said cardiac signals, controlling delivery of one or more electrical cardioversion/defibrillation countershocks of at least 0.5 Joules to said patient; capacitor means within said interior space for storing electrical energy to generate said electrical cardioversion/defibrillation countershocks and having an effective capacitance of less than about 80 μ F; and battery means within said interior space for providing electrical energy to said circuit means and said capacitor means and capable of charging said capacitor means in less than about 10 seconds to a maximum electrical charge energy of less than about 25 Joules, wherein the total amount of electrical energy stored by said battery means is less than 12,000 Joules and the budgeted number of electrical cardioversion/defibrillation countershocks is less than about 200.

To understand how the present invention can use a minimum effective current I_{pe} to insure an appropriate safety margin for the ICD, it is necessary to recognize that the objective of any defibrillation countershock is to generate an electric field across as much as possible of the heart muscle, the myocardium. This electric field must have a current strong enough to extinguish all cardiac depolarization wavefronts in the myocardium, and the current must be strong enough to prevent the myocardium cells from being restimulated during their vulnerable period. In essence, the present invention recognizes that the electric current generated by the defibrillation countershock must be larger than whatever

minimum electric current is required for cell stimulation by at least a sufficiency ratio that will insure successful defibrillation. In this way, the use of an effective current I_{pe} can be thought of as a correction factor applied to the actual current of the defibrillation countershock in order to
5 compensate for the cellular phenomenon that currents below some minimum value simply do not have any effect on the cells.

It has long been known that in order to stimulate cells, a current applied to those cells must have a value at least equal to a rheobase value of those cells, otherwise the current applied to the cells is not effective in
10 stimulating the cells. G. Wiess, "Sur la Possibilite de Rendre Comparable entre Eux les Appareils Suivant a l'Excitation Electrique", Arch. Ital. de Biol., Vol. 35, p. 41 (1901); and L. Lapicque, "Definition Experimetelle de l'excitabilite", Proc. Soc. de Biol., Vol. 77, p. 280 (1909). Lapicque defined the rheobase value as the stimulating current required for a pulse of infinite
15 duration. From this definition, he further defined a chronaxie value (d_c) to be the duration of a pulse that required a current twice that of the rheobase value. These two works have been combined in the literature to define a strength-duration model for the required average current for neural stimulation known as the Weiss-Lapicque strength-duration curve,
20 an example of which is shown in Fig. 12.

The present invention builds on the Weiss-Lapicque strength-duration model to define a physiologically effective current I_{pe} as a simple model for the efficiency of a monophasic defibrillation countershock in terms of the actual average current of the defibrillation countershock. The
25 actual average current (I_{ave}) is given by the amount of electrical charge delivered at the electrode leads divided by the duration of the pulse delivering that charge. The end result of the derivation of a definition of effective current I_{pe} as taught by the present invention is that the effective current I_{pe} is given by the charge delivered to the electrode leads divided
30 by the sum of the pulse duration (d) and the chronaxie time constant for the heart (d_c). Expressing the charge delivered to the electrode leads in terms of the actual average current I_{ave} yields a definition equation as

follows:

$$I_{pe} = (I_{ave} * d) / (d + d_c) \quad (\text{Eq. 5})$$

It can be seen from Eq. 5 that if the chronaxie value d_c were zero, the effective current I_{pe} would simply be I_{ave} , the average current of a monophasic defibrillation countershock. In this way, the definition of an effective current I_{pe} distills the information contained in the Weiss-Lapicque strength duration curve to correct the actual average current I_{ave} of a monophasic defibrillation countershock in order to compensate for the chronaxie phenomenon of the cells of the myocardium.

When a minimum effective current I_{pe} is used to select and arrange the internal components of a capacitor-discharge ICD, the end result is a pair of surprising and non-intuitive conclusions.

First, the optimum capacitance value for the capacitor in a capacitor-discharge ICD is not determined by any stored or delivered energy requirement, but instead is a relatively constant value much smaller than any currently used capacitance values. The use of a minimum effective current I_{pe} predicts that the optimum capacitance value will be a function of only the chronaxie time constant and the inter-electrode resistance of the electrode leads. This means that a capacitor with a smaller effective capacitance actually delivers a defibrillation countershock with more effective current I_{pe} than a capacitor having a larger effective capacitance. When the optimum capacitance value is analyzed in terms of effective current I_{pe} , it is found that the optimal capacitance value is given by the formula:

$$C = (0.8 * d_c) / R \quad (\text{Eq. 6})$$

Second, there is no single optimum pulse duration for a defibrillation countershock having an arbitrary capacitance value. Instead, a defibrillation countershock of a shorter duration can provide a more effective current I_{pe} than a defibrillation countershock of a longer duration. The use of a minimum effective current I_{pe} predicts that the optimum pulse duration is a compromise between the RC time constant of the capacitor-discharge circuitry and the heart's defibrillation chronaxie

time constant, d_c . Thus, the predicted optimum pulse duration is not a constant, but rather is a function of the effective capacitance and other variables. The predicted optimum pulse duration can be most simply, and robustly, expressed as a fixed tilt or exponential decay followed by a fixed
5 time duration extension. When the optimum pulse duration value is analyzed in terms of effective current I_{pe} , it is found that the optimal pulse duration is given by the formula:

$$d = ((R * C) + d_c) / (e - 1) \quad (\text{Eq. 7})$$

Because the physical size of the capacitor is a function of its
10 capacitance rating, the use of a capacitor with a smaller effective capacitance provides for a significant reduction in the displacement volume of the capacitor. In addition, because less energy is required to charge up a capacitor with a smaller effective capacitance, a battery with a smaller total energy storage, and, hence, a smaller displacement volume,
15 may also be used. Finally, the shortening of the duration of the defibrillation countershock further decreases the energy requirements of both the capacitor and the battery, and also improves the safety margin of the device. In the preferred embodiment, several additional innovations are also used to further enhance the effectiveness of the defibrillation
20 countershock and decrease the energy storage requirements of the ICD.

As a result of all of these improvements in the selection and arrangement of the internal components of the ICD of the present invention, the capacitor in the device only needs to store a maximum E_c of less than about 30 Joules, and preferably less than 27 Joules. The
25 effective capacitance of the capacitor required by the present invention can be less than 120 μF , and preferably less than about 95 μF . By optimizing both the charging time and the countershock duration for the smaller maximum E_c , the size of the battery required by the present invention is reduced because the total energy storage capacity of the device can be less
30 than about 1.0 Amp-hours. In the preferred embodiment, the charging time for each defibrillation countershock is reduced to less than about 10 seconds and the pulse duration of a monophasic defibrillation

countershock, or of a first phase of a multiphasic defibrillation countershock, is reduced to less than about 6 milliseconds.

By significantly reducing the displacement volume of both the capacitor and the battery, the overall displacement volume of an ICD in accordance with the present invention can be reduced below 90cc, and preferably to between 40-80cc, and with current capacitor and battery technology between about 50-70cc. Because the size requirements for effective pectoral implantation will be distributed across the range from 40-90cc for the entire population, it is obvious that the smaller the overall displacement of the ICD, the greater the percentage of human patients who can benefit from pectoral implantation of the device. At the displacement volumes provided for by the present invention, subcutaneous implantation of the device in the pectoral region of a human patient can be quite practical and effective.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a frontal plan view showing the automatic, implantable cardioverter defibrillator of this invention implanted in the pectoral position of a human patient.

20 Figs. 2 and 3 are frontal and side plan views, respectively, of the preferred embodiment of the ICD of the present invention.

Figs. 4 and 5 are side and frontal plan views, respectively, showing the power, capacitor, circuit and connector ports means positioned in the preferred embodiment of the ICD of the present invention.

25 Figs. 6 and 7 are plan views, showing the interior of the preferred embodiment of the ICD of the present invention.

Fig. 8 is a voltage versus time graph showing the relative distribution of the defibrillation energy discharged from the capacitor of the preferred embodiment of the ICD of the present invention.

30 Figs. 9 and 10 are voltage versus time graphs and a comparison table, respectively, showing the defibrillation energy discharged from the capacitor used in the preferred embodiment of the ICD of the present

invention versus the defibrillation energy discharged from a capacitor in a prior art ICD.

Fig. 11 is a defibrillation success curve used to define a minimum defibrillation threshold (DFT) for prior art ICDs for monophasic intravenous defibrillation countershocks.

Fig. 12 is a typical Weiss-Lapicque strength-duration curve showing the average current required for defibrillation as a function of the pulse duration.

Fig. 13 is a defibrillation success curve for the present invention using an physiologically effective current (I_{pe}) for monophasic intravenous defibrillation countershocks.

Fig. 14 is a graph of the minimum effective current (I_{pe}) for monophasic intravenous defibrillation countershocks versus fibrillation time showing the impact of prolonged fibrillation on minimum I_{pe} .

Fig. 15 is a graph of the minimum effective current (I_{pe}) for monophasic intravenous defibrillation countershocks as a function of electrode resistance for both fixed duration and tilt countershock pulses.

Fig. 16 is a block diagram of a dual battery system energy storage system for the preferred embodiment of the present invention.

Fig. 17 is a block diagram of a rechargeable version of the dual battery system shown in Fig. 16.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The following detailed description, when considered in connection with the accompanying drawings in which like reference numerals designate like parts throughout the figures, describes some of the embodiments of the present invention. In describing the present invention, first a description of the preferred mechanical arrangement of the internal components of the implantable cardioverter defibrillator (ICD) will be presented to provide a context for the remainder of the description. Next, a mathematical explanation of the derivation of the physiologically effective current (I_{pe}) as used by the present invention will

be presented. Then, each of the major features responsible for decreasing the overall displacement volume of the ICD will be described. These features include: the use of a more optimal pulse duration and pulse waveform for the cardioversion/defibrillation countershock, the use of a capacitor having a smaller effective capacitance value, and the use of an improved battery configuration having a smaller total energy storage.

Mechanical Arrangement of the ICD Components

Fig. 1 shows an automatic ICD 17 of the present invention implanted in the pectoral region 18 of the chest 11 of patient 10. The ICD 17 has a plurality of connector ports for connection to various implantable catheter and other electrode means, as is known in the art. For example, electrode leads 41 and 42 are shown extending from the ICD 17 to catheter electrodes 40 and 15 which are passed, respectively, into the superior vena cava 14 and the right ventricle 13 of heart 12. Further, lead 43 is shown extending from the ICD 17 to a subcutaneous patch electrode 16. The specific configuration of the electrodes of the defibrillation system is dependent upon the requirements of the patient as determined by the physician.

Figs. 2 and 3 show the ICD 17 comprised of a housing 19 having mating half shells 21 and 22. Positioned and mounted on top of housing 19 is a top connector portion 20 having a plurality of connecting ports 23 which are described further below. Importantly, the ICD 17 is comprised of a compact, self contained structure having predetermined dimensions which permits pectoral implantation. The housing 19 and top connector 20 are constructed and arranged to yield a cooperating structure which houses power means, control means and capacitive means. This cooperating structure permits subcutaneous implantation in the pectoral region of a human patient and provides a compact and effective ICD that automatically senses the bioelectrical signals of the heart and is able to provide a 750 volt capacitive discharge, for example, to the heart for defibrillation purposes.

In the past, ICDs have required a size and configuration for functional purposes that necessitated implantation in the abdominal cavity of a patient. Such implantation has resulted in patient discomfort. However, the physical parameters of these prior art devices have prevented pectoral implantation, which is preferred by physicians and patients alike. Table 1 below shows the size and weight comparisons between known prior art ICD devices and the ICD 17 of the present invention.

TABLE 1

Device Art	Prior Art Device total (by volume)	Present Device % of total (by volume)	Present Device % of Prior Art Devices (by volume)	Present % of Prior Devices (by weight)
Connector	10	8	30	32
Capacitors	30	38	63	62
Batteries	30	23	38	57
Electronics	<u>30</u>	<u>31</u>	<u>50</u>	<u>40</u>
Total	100%	100%	50%	55%
	(120CC)	(60CC)		

As shown in Table 1, the ICD 17 of this invention, provides a structure which is 50% of the volume of prior art devices and which has a weight which is 55% of the weight of the prior art devices. The connector port, capacitor, battery and electronic circuitry of the ICD 17 of the present invention are further described below.

It is important in this invention that the ICD 17 be constructed and arranged to minimize the overall displacement volume of the device to allow for pectoral implantation, for example. The housing structure 19 is a compact and lightweight structure made of a biocompatible material and

has a contoured configuration. The overall structure of this invention has a weight of less than 130 grams, and preferably less than 120 grams, and a volume of less than 90cc, and preferably between about 40-80cc. As shown in Table 1, the ICD 17 of this invention has generally 55% of the weight of prior art devices and a volume which is generally 50% of that of prior art devices. Table 1 further shows the weights and volumes of the respective components of this invention (connector, capacitor, batteries and electronics) as a percentage in weight and volume of the total and in comparison to prior art devices.

As further shown in Figs. 2 and 3, the housing structure 19 has a contoured periphery which is matingly connected to the top connector member 20 which also has a mating contoured configuration. The housing 19 is constructed of a biocompatible material such as a titanium or a stainless steel alloy. The top connector member 20 is also constructed of a biocompatible material, such as a biocompatible polymeric composition. It has further been found that for pectoral implantation purposes, that the housing structure 19 have a desired length to width to thickness ratio of approximately 5 to 3 to 1.

When selected in accordance with the optimized minimum physiological current (I_{pe}) as described below, the capacitor has an effective capacitance of approximately 85 μF , is constructed and arranged to deliver an initial discharge voltage V_d of 750 Volts, yielding the effective defibrillation countershock which is also described below. In the preferred embodiment, the effective discharge voltage and capacitance is achieved by using two flash-type capacitors in series, each having a capacitance rating of 170 μF and a voltage rating of 375 Volts, while occupying a total displacement volume of only 7cc each. The output of the capacitors is in communication with an electronic circuitry output portion that generally is comprised of a flash type circuit which delivers the capacitor discharge through electrodes 15, 16 and 40, for example.

Figs. 4 and 5 show the canister housing 19 having an interior space wherein capacitors 26 and 27 are positioned and wherein a battery

system 28 and circuit board portions 31 and 32 are positioned. The top connector 20 is shown mounted to the top of the canister housing 19. Connecting ports 36, 37 and 39 are shown positioned in the top connector 20. The connector ports 36 and 37 are connectible to the positive
5 defibrillating electrode, for example, while connecting port 38 is connectible to the negative defibrillating electrode, for example, and the connecting port 39 receives the pacing/sensing electrode leads 41, 42. Channels 24 and 25 provide communicative and fastener members that provide for the attachment of the top connector 20 to the canister housing
10 19 and for the electrical connection between the ports 36, 37, 38 and 39 and the electronic elements positioned in the interior space 30 of housing 19.

As discussed, the top connector 20 of the defibrillator ICD 17 has, for example, connecting ports 36 (DF+), 37(DF+), 38(DF-) and 39 (sensing/pacing). The lead connected to the DF- port, for example, is in
15 conductive contact with the catheter electrode 15 placed in the right ventricle 13 of the heart 12. The electrode lead(s) connected to the DF+ port(s) are connected to either or both of the electrodes positioned in the superior vena cava 14 and the subcutaneous patch electrode 16. Alternatively, the DF+ port holes may not be utilized, and plugged by a
20 stopper means, for example, when the ICD body itself is utilized as the positive element to complete the defibrillation circuit. The pacing/sensing electrode 44 provides an input to connecting port 39 of the ICD 17 and provides continual monitoring of cardiac signals from the heart. The circuitry of the ICD 17 has means to detect any tachycardiac or
25 other arrhythmia condition and to thereby respond by the selective discharge of electrical energy stored in the capacitors 26 and 27.

As described in more detail below, the ICD 17 of this invention provides a device which utilizes smaller capacitors and batteries than those of prior art devices and thus yields a countershock generator device
30 having a smaller displacement volume that permits effective implantation of the device in the pectoral region of a human patient. Although the smaller unit and associated components are smaller and

deliver a smaller energy countershock to the heart, the implantation of the device in the pectoral region provides for a better countershock vector. Together with the improved countershock pulse waveform as described below, the ICD 17 produces a more effective defibrillation/cardioversion
5 countershock than prior art ICD devices.

Figs. 6 and 7 show the mating housing half shells 21 and 22, respectively of canister housing 19. The half shell 22 is shown to have an interior peripheral band 34 which is fixed adjacent the peripheral edge 33. The interior peripheral band 34 extends outwardly from the edge 33 of half
10 shell 22 and is constructed and arranged to receive the peripheral edge 35 of housing half shell 21. Alternatively, the peripheral band 34 may be mounted within housing half shell 21, whereby the half shell 22 is positioned thereabout. The peripheral band 34 is also provided to shield the electronic components within housing 19 during the welding process
15 uniting the body shells 21 and 22.

The flexible circuit board 29 is mounted within the interior space 30 of housing 19. The circuit board 29 provides for the sensing/pacing circuitry in communication with the lead extending from connecting port 39, for example. When a fibrillation episode is detected, the circuit board
20 29 causes the capacitors 26, 27 to discharge an initial 750 Volt charge through the electrode leads connected to ports 36-38, for example, and to the heart 12 of the patient 10. The electronic circuitry has a sensing portion which monitors the heart beat rate irregularity by means of two small electrodes 44, as is known in the art. In the preferred embodiment,
25 the circuitry further has a processor portion which determines, with respect to a predetermined standard, when the output portion of the circuit will be activated.

Fig. 8 is a graph showing the voltage discharge with respect to time from the 85 μ F capacitor used in the preferred embodiment of the ICD 17
30 of this invention. The graph shows the incremental benefit of the voltage discharge with respect to time. Fig. 9 is a graph which shows the instantaneous voltage with respect to time and compares the plotted

values of a countershock having the same delivered energy content for both the present invention and a typical prior art ICD. In Fig. 9, the countershock is a 20 Joule delivered energy monophasic countershock and it will be seen that the pulse duration of the countershock in accordance with the present invention is significantly shorter than the pulse duration of the countershock delivered by the prior art ICD.

As summarized in the table of Fig. 10, the 85 uF capacitor of the preferred embodiment of the present invention provides 25.33 Joules of delivered energy in the form of a biphasic defibrillation countershock having a delivery efficiency of 97.5% from a 26 Joule maximum E_c stored in the capacitors 26, 27. In comparison, the 140 uF capacitor used in a prior art ICD device provides 34 Joules of delivered in the form of a monophasic defibrillation having a delivery efficiency of 86.3% from a maximum E_c stored in the capacitor of 39.4 Joules. The effective current I_{pe} of the biphasic countershock delivered by the present invention is 5.67 Amps, uncorrected, and possibly as high as 6.55 to 7.32 Amps, when corrected to be a monophasic equivalent current. In contrast, the effective current I_{pe} of the monophasic countershock delivered by the prior art device is 6.79 Amps. Thus, the uncorrected I_{pe} of the present invention is only 20% less than the I_{pe} of the prior art device, while the maximum E_c of the present invention is more than 50% less than the maximum E_c of the prior art device.

When the corrected I_{pe} provided by the biphasic countershock of the preferred embodiment of the present invention is compared, the present invention provides essentially the same effective current I_{pe} as the prior art device with half the maximum E_c and, as little as half the requisite displacement volume for the capacitor. Depending upon the correction factor applied to convert the current efficiency of an optimized biphasic countershock pulse to a traditional monophasic countershock pulse (a 25% more energy efficient countershock is a 15% more efficient effective current, whereas a 40% more energy efficient countershock is a 28% more efficient effective current), the corrected I_{pe} of the present invention is

between 3% less to 7% more than the I_{pe} of the prior art device.

Derivation of the Physiologically Effective Current (I_{pe})

The famous Weiss-Lapicque model was developed at the turn of the century. It was an empirical model and the first physiological explanation for why the model accurately predicts the required current for cellular stimulation was only recently explained. Irnich, W., "The Fundamental Law of Electrostimulation and its Application to Defibrillation", PACE 1990, 13 (Part 1): 1433-1447. The model gives the required (average) current for neural stimulation as:

$$I_{ave} = K_1 + (K_2 / d) \quad (\text{Eq. 8})$$

with d being the pulse duration. The value K_1 is the current required for an infinite duration pulse. The "chronaxie" is that duration which requires a doubling of the rheobase current. The chronaxie time constant d_c is thus given by:

$$d_c = K_2 / K_1 \quad (\text{Eq. 9})$$

Defining I_r as the rheobase current gives:

$$I_{ave} = I_r * [1 + (d_c / d)] \quad (\text{Eq. 10})$$

The Weiss-Lapicque model was based on cell stimulation, not defibrillation. However, in 1978, Bourland et al showed, with a study of dogs and ponies, that defibrillation thresholds also followed the Weiss-Lapicque model when current averaged over pulse duration was used. Bourland, J.D., Tacker, W.A. and Geddes, L.A., "Strength Duration Curves for Trapezoidal Waveforms of Various Tilts for Transchest Defibrillation in Animals", Med. Instr., (1978), Vol. 12, No. 1:38-41. A typical strength-duration curve is shown in Fig. 12.

Bourland et al. further proposed that the average current of a pulse was the best measure of its effectiveness when compared to other pulses of the same duration. This was found to hold fairly true for pulses from 2-20 ms in duration, regardless of waveform. Bourland, J.D., Tacker, W.A. and Geddes, L.A., et al. "Comparative Efficacy of Damped Sine Wave and Square Wave Current for Transchest Ventricular Defibrillation in

Animals", Med. Instr., (1978), Vol. 12, No. 1:42-45.

Numerous studies have confirmed the strength-duration relationship for defibrillation currents. These same studies show that the defibrillation chronaxie time constant, d_c , is in the range of 2-4 ms. Using
 5 the available data on measured defibrillation chronaxie time constants, d_c
 $= 2.7 \pm 0.9$ ms is the average chronaxie value for the human heart.

In contrast to the accepted prior art technique of using a minimum defibrillation threshold energy (DFT) to measure the effectiveness of a defibrillation countershock, or even in contrast to the suggestion by
 10 Bourland et al to use the average current, the present invention defines an effective current as that percentage of the rheobase requirement for the human heart that the average current of a defibrillation countershock pulse can satisfy. Under this definition, successful defibrillation will require that

$$15 \quad I_{ave} \geq I_r * [1 + (d_c / d)] \quad (\text{Eq. 11})$$

where I_{ave} is the current averaged over the pulse duration of the defibrillation countershock. Satisfying this condition and substituting I_{pe} for I_r yields a definition of physiologically effective current (I_{pe}) which can be expressed in several ways:

$$20 \quad I_{pe} = I_{ave} / [1 + (d_c / d)] \quad (\text{Eq. 12})$$

$$= (I_{ave} * d) / (d_c + d) \quad (\text{Eq. 13})$$

$$= \text{delivered charge} / (d_c + d) \quad (\text{Eq. 14})$$

Note that the effective current of a defibrillation countershock only equals the rheobase current when the output of the pulse is exactly
 25 operated at the defibrillation threshold, and, hence, with a zero safety margin. In general, the two parameters are not equal in value or orientation. The effective current I_{pe} is a system variable of the ICD, while the rheobase current I_r is primarily a physiologic variable.

Fig. 13 shows a defibrillation success curve for monophasic
 30 intravenous defibrillation countershocks plotted in terms of the effective current I_{pe} of the present invention. It will be apparent when comparing

the I_{pe} defibrillation success curve shown in Fig. 13 with the DFT defibrillation success curve shown in Fig. 11 that the I_{pe} curve is tighter and the necessary safety margin is much closer to the median I_{pe} required for effective defibrillation. Fig. 14 is a graph of the minimum I_{pe} for monophasic intravenous defibrillation countershocks versus fibrillation time showing the impact of prolonged fibrillation on minimum I_{pe} . Together, these figures illustrate how a device with a smaller maximum E_c can still provide a more than adequate safety margin, as long as the effective current I_{pe} of the defibrillation countershock is sufficient. The next two sections of the description set forth how to optimize the characteristics of a cardioversion/defibrillation countershock in terms of effective current I_{pe} .

Optimal Pulse Waveform and Duration

The present invention uses the effective current I_{pe} model to find the optimum pulse duration for a conventional, time-truncated, capacitor discharge defibrillation countershock waveform. In such a capacitor-discharge system, a capacitance (C) is charged to an initial voltage (V_i) and then discharged into the effective load resistance (R) of the heart for a pulse duration (d), at which time the capacitance will have a final voltage (V_f). The amount of droop in the capacitor-discharge waveform at the time the pulse is truncated has been referred to as the "tilt" of the waveform as given by the equation:

$$\text{tilt} = (V_i - V_f) / V_i \quad (\text{Eq. 15})$$

$$= 1 - V_f / V_i$$

Substituting the RC time constant exponential decay for V_f / V_i yields:

$$\text{tilt} = 1 - e^{-d/RC} \quad (\text{Eq. 16})$$

where RC is the capacitor-discharge system time constant, also known as τ .

Substituting the system parameters for C, V and tilt for the delivered charge in Eq. 14, the effective current I_{pe} can also be expressed as:

$$I_{pe} = (C * V * \text{tilt}) / (d_c + d) \quad (\text{Eq. 17})$$

$$= (C * V * (1 - e^{-d/\tau})) / (d_c + d)$$

Because the first derivative of I_{pe} approaches zero at extreme values of d , its maximum is at the point of zero derivative.

$$0 = \partial I_{pe} / \partial d \quad (\text{Eq. 18})$$

$$\begin{aligned} &= CV_1 [[(d_c + d) [1/\tau e^{-d/\tau}] - [1 - e^{-d/\tau}]] / (d_c + d)^2] \\ &= [(d + d_c)/\tau] e^{-d/\tau} - 1 + e^{-d/\tau} \\ &= [[(d + d_c)/\tau] + 1] e^{-d/\tau} - 1 \end{aligned}$$

Normalizing Eq. 18 to the system time constant by defining:

$$z = d / \tau \quad (\text{Eq. 19})$$

$$\alpha = d_c / \tau \quad (\text{Eq. 20})$$

The derivative of Eq. 18 now reduces to

$$0 = (z + \alpha + 1) e^z - 1 \quad (\text{Eq. 21})$$

Multiplying by $-e^z$ and defining $f(z)$ gives:

$$0 = e^z - z - \alpha - 1 \equiv f(z) \quad (\text{Eq. 22})$$

15 This transcendental equation cannot be solved in closed form, so the Newton-Raphson approximation is used. If z_0 is the first approximation for the root, then $z' = z_0 - (f(z_0) / f'(z_0))$ is the Newton-Raphson approximation for Eq. 22. Present ICD devices favor a tilt of about 65%. This implies that the countershock pulse duration is roughly
20 equal to one system time constant ($d = \tau$). Because $z = d / \tau = 1$, the first approximation is $z_0 = 1$. Thus:

$$z' = z_0 - (f(z_0) / f'(z_0)) \quad (\text{Eq. 23})$$

$$\begin{aligned} &= 1 - [(e - 1 - 1 - \alpha) / (e - 1)] \\ &= (1 + \alpha) / (e - 1) \end{aligned} \quad (\text{Eq. 24})$$

25 Denormalizing Eq. 24 gives:

$$d \approx \tau [(1 + (d_c / \tau)) / (e - 1)] \quad (\text{Eq. 25})$$

This gives the expression for optimal pulse duration of a time truncated monophasic capacitor discharge:

$$d = (\tau + d_c) / (e - 1) \quad (\text{Eq. 26})$$

Numerical optimization shows that this estimate gives an I_{pe} within 0.2% of true optimum for typical values of R , C and d_c . For extreme values the maximum error in the resulting I_{pe} is less than 2.0%. It should also be noted that $(e - 1) = 1.72 \approx 2$. Thus, the optimal pulse duration, d , is approximately equal to the average of the capacitor time constant and the heart's chronaxie time constant. In other words, the model suggests that the best pulse duration is a compromise between the time required to deliver the capacitor's charge, $\tau = RC$, and the time required to match the timing of the heart, d_c .

The predicted optimum d may be used to directly derive the optimum tilt for the countershock pulse from Eqs. 16 and 26.

$$\begin{aligned} \text{tilt}_{\text{opt}} &= 1 - e^{-d_{\text{opt}}/\tau} \\ &= 1 - \exp[-(1 + (d_c/\tau))/(e - 1))] \end{aligned} \quad (\text{Eq. 27})$$

where, again, $\tau = RC$. Assume, for a moment, that RC is chosen to equal d_c . From Eq. 27 we have that $\text{tilt}_{\text{opt}} = 68.8\%$.

It will be noted that the predicted optimum tilt is rather high for small capacitance values. An intuitive explanation is that they need to spread their charge delivery over as great a duration as possible to come closer to the chronaxie time. Because the rheobase is small compared to the peak current, this lowering of average current is well tolerated. Conversely, for large capacitances the optimum tilt is smaller as the average current must remain above the rheobase.

The prediction by this model that small capacitor systems benefit from higher tilts is supported, but not predicted, by a prior study of truncated waveforms. Schuder, J.C. et al. "Transthoracic Ventricular Defibrillation in the Dog with Truncated and Untruncated Exponential Stimuli", IEEE Trans. Bio. Eng. (1971); BME-18:410-415. This study shows that the greatest improvements from truncation are obtained with pulses with $d > 5$ ms. In other words, high tilts are better tolerated with smaller pulse durations (which are generated by smaller capacitors).

It will be understood that the inter-electrode resistance varies with the patient and positioning of the electrode leads and may change after implantation of the ICD. It is desirable that the pulse duration d remain close to optimum in spite of this change. Fig. 15 gives the effective current I_{pe} for various inter-electrode resistances when the tilt and duration of the pulse were optimized for an assumed 50Ω load. In this example, a $140\mu F$ capacitor and a $2.7ms$ chronaxie are assumed. One curve shows how the effective current I_{pe} varies when tilt is used as the specification for the pulse duration, while the other reflects the use of a fixed time duration. Note that tilt best tolerates decreases in resistance while a fixed duration best handles increases in resistances.

The optimum pulse duration from Eq. 26 may be rewritten as:

$$d = 0.58 RC + 0.57d_c \quad (\text{Eq. 28})$$

Because $1 - e^{-0.58} = 44\%$, a pulse duration of $0.58 RC$ may be redefined as a 44% tilt. Thus, the optimum duration from Eq. 28 may be stated in words as:

1. Allow the capacitor voltage to decay by 44%, then
2. Continue the pulse for an additional 58% of the chronaxie time constant.

If we assume $d_c = 2.7 ms$, then this gives a 44% tilt followed by a $1.6ms$ extension for optimum pulse duration. Note that this specification of the optimum pulse duration automatically adjusts the duration for any changes in resistance so that continued monitoring of the effective inter-electrode resistance is not required. In addition, using this specification of the optimum pulse duration gives an I_{pe} in excess of that specified by either a fixed tilt or a fixed duration alone, for any resistance value.

The choice of a tilt or duration specification has been an open issue in defibrillation. Based on the predictions using the effective current model of the present invention, it would appear that the best choice is actually a composite of tilt and duration as given in Eq. 28. This specification for pulse duration is intuitively attractive in that it directly recites the necessary compromise between the electronics (duration

sufficient for charge delivery) and the heart (duration close to chronaxie for efficiency).

The optimized pulse duration utilized by this invention can be applied to monophasic waveforms, or the first phase of a biphasic or multiphasic waveform. In the latter cases, when it is applied to the first phase of a waveform, subsequent phases of the waveform can be specified to have equal or lesser duration than the first phase. In the preferred embodiment, a biphasic waveform is used in order to take advantage of the additional decrease in the minimum effective current I_{pe} required for effective defibrillation that is predicted by known clinical data showing a 25-40% decrease in minimum DFT energy thresholds for biphasic countershock pulses.

It will also be appreciated that the optimum pulse waveform and durations predicted by the use of the present model of effective current I_{pe} are equally applicable to both cardioversion and defibrillation countershocks. Typically, cardioversion countershocks are countershocks that have total pulse energies of between 0.5 and 5 Joules, whereas defibrillation countershocks are countershocks that have total pulse energies greater than about 3 Joules. In each case, the present invention utilizes cardioversion/ defibrillation countershocks which have pulse durations and waveforms optimized in terms of effective current I_{pe} to produce a smaller total energy required for an effective countershock pulse.

25 Smaller Effective Capacitance Value

For a given capacitor technology, capacitor volume is proportional to the stored energy. To maximize the performance of an ICD, for a given displacement volume, one must therefore optimize the effective current I_{pe} for a given maximum E_c as defined by Eq. 1. Reworking Eq. 1 in terms of V_d :

$$V_d = ((2 * E_c) / C)^{0.5} \quad (\text{Eq. 29})$$

Combining Eq. 29 with the effective current I_{pe} formula of Eq. 17

yields:

$$\begin{aligned} I_{pe} &= (C * V * \text{tilt}) / (d_c + d) \\ &= (C * ((2 * E_c) / C)^{0.5} * \text{tilt}) / (d_c + d) \\ &= ((2 * E_c)^{0.5} * C^{0.5} * \text{tilt}) / (d_c + d) \quad (\text{Eq. 30}) \end{aligned}$$

5 Substituting Eq. 26 for d and Eq. 27 for the optimum tilt gives:

$$\begin{aligned} I_e &= \frac{\sqrt{2E} \sqrt{C} \left\{ 1 - \exp \left[\frac{1 + d_c / RC}{1 - e} \right] \right\}}{\frac{RC + d_c}{e - 1} + d_c} \\ &= \sqrt{2E} \frac{\sqrt{C} \left\{ 1 - \exp \left[\frac{1 + d_c / RC}{1 - e} \right] \right\}}{\frac{RC + d_c}{e - 1} + d_c} \quad (\text{Eq. 31}) \end{aligned}$$

Note that the term for energy can be separated from the remainder of the expression. Thus, the optimum capacitance value is independent of the stored energy in the capacitor. The numerical solution is:

$$(R * C) / d_c = 0.795906 \approx 0.8 \quad (\text{Eq. 32})$$

The solution is a reasonable result that implies that an RC time constant of the countershock pulse should be close to the "time constant" of the myocardial cells (i.e., the chronaxie value time constant) for optimum performance of the cardioversion/defibrillation countershock. This solution is accurate to 1% over a broad range of the exogenous variables R and d_c . The solution also suggests that there is no first order relationship between energy storage and optimum capacitance. In other word, to change the energy of an ICD, the effective current model of the present invention suggests that ideally the voltage should be adjusted up or down, and that the capacitance should not be moved significantly from the ideal value.

Assuming a chronaxie of 2.7 ms and inter-electrode resistance of 50 Ω , the optimum capacitance value from Eq. 32 is 43 μF . Using this capacitance value in Eq. 26 yields a pulse duration of 2.83 ms. This corresponds to a tilt value of approximately 73% (see Eq. 27). It will be

noted that the 2.83 ms optimal duration is very close to the 2.7 ms assumed chronaxie time. Thus, the optimal pulse duration for the practical capacitive discharge pulse is close to that of an ideal rectangular pulse as represented by the chronaxie time constant, assuming that the capacitance value is optimized to about 43 μF .

As shown in Fig. 10, a presently approved ICD delivers a maximum defibrillation countershock monophasic pulse with an effective current I_{pe} of 6.79 Amps from a 140 μF capacitor charged to 750 Volts. This requires a minimum E_c of at least 39.4 Joules and a corresponding requisite volume for this storage. If the optimum capacitor value of 43 μF and a tilt of 73% were used, the same 6.79 Amps effective current I_{pe} could be delivered from a charge of 1195 Volts that would involve an energy storage of only 30.7 Joules. In other words, the less efficient design of existing ICDs with overly large capacitors requires 28% more energy that requires 28% more capacitor volume for the device to deliver a monophasic countershock. As previously described, the battery volume in existing device is necessarily larger to supply this increased minimum E_c .

As indicated in the background art section, when designed with present day microelectronic switches, such as power FETs, the optimal discharge voltage V_d of almost 1200 Volts is problematical. Thus, in the preferred embodiment a compromise in capacitor size is necessary. As a result, the optimum capacitance value selected for a discharge voltage V_d of 750 Volts is approximately 85 μF . As a result, the effective current I_{pe} delivered by the preferred embodiment is 5.67 Amps. When the 13-29% increased efficiency of the effective current of a biphasic waveform is factored in, the present invention provides a monophasic equivalent effective current of between 6.55 to 7.32 Amps. Thus, the preferred embodiment that stores a maximum E_c of about 26 Joules can actually be more effective than the prior art monophasic defibrillation countershocks that required a maximum E_c of 39.4 Joules, yet only produces an effective current I_{pe} of 6.79 Amps. In addition, this compromise on capacitor size of the preferred embodiment permits a simple implementation of the

capacitor-discharge ICD, while obtaining the majority of the benefits of the reduced size of the capacitor, and, the corollary reduction in the size of the battery.

5 Improved Battery Configuration

For the battery, the physical size of the battery will be primarily a function of the amp-hours of storage capacity provided by the battery. In addition to the required maximum E_c , two other energy parameters are required in order to budget the storage capacity of a battery for an ICD.

- 10 These parameters are the minimum number of countershocks that are to be delivered over the life of the device (N_p) and the idle current drain of the device when it is sensing the cardiac signals (I_i). Current ICDs budget for at least 200 defibrillation countershocks over the life of the device and idle currents are on the order of 15-20 μ Amps.

- 15 Some ICDs also provide for pacing capabilities, in which case the required pacing energy must also be factored into the storage capacity of the battery. The current draw on a battery due to constant pacing can be estimated by assuming that the pacing countershock will have a 6 Volt amplitude, a 500 μ sec width, and a 500 Ω assumed impedance, and that
20 pacing will occur at a rate of 70 beats/minute. Under these conditions, the energy drawn from the battery will be about 2.5 mJoules/minute, or an average current draw of about 7 μ Amps. It should be noted that the electrical energy necessary to provide for pacing capabilities is much less than even the idle current drawn by the ICD.

- 25 If an ICD is designed against an optimum battery budget that would support a device life (l) of five years, the total storage capacity (E_t) required for the battery is the sum of the maximum electrical charge energies, the maximum idle current energies and the maximum pacing energies. For existing ICDs, such a battery budget can be calculated as follows:

30

$$\begin{aligned}
 E_t &= ((I_b * t_c) * N_p) + (I_i * l) + (I_p * l) & \text{(Eq. 33)} \\
 &= (12 \text{ Amp-sec} * 200) + (20\mu\text{A} * 5 \text{ years}) + (7\mu\text{A} * 5 \text{ years}) \\
 &= (0.7 \text{ Amp-hours}) + (0.9 \text{ Amp-hours}) + (0.3 \text{ Amp-hours})
 \end{aligned}$$

= 2.0 Amp-hours

Most ICDs use a pair of 3 Volt, 2 Amp-hour lithium/silver vanadium oxide batteries to provide this amount of total storage capacity for the ICD. The lithium/silver vanadium oxide batteries represent the
5 densest power source technology currently viable for use in an ICD. While improvements in battery technology may increase the storage density slightly, and thereby decrease the total volume of the power source somewhat, the total volume required by the power source for current ICDs must be sufficiently large to supply a total storage capacity (E_t) for the
10 device of about 2.0 Amp-hours.

In contrast to the prior art, the present invention budgets a total storage capacity E_t for the device of about 1.0 Amp-hours. This significantly smaller storage capacity E_t is achieved primarily due to the smaller maximum E_c for the device. Additionally, several innovations in
15 capacitor charging and battery configuration of an improved battery system are utilized in the preferred embodiment to further reduce both the storage capacity E_t and the overall displacement volume of the battery system. These innovations include: (1) the use of a dual battery configuration, one battery for the monitoring requirements and a different
20 battery for charging the capacitor; (2) the use of a battery budget designed more appropriately for a prophylactic ICD system that has a fewer total number of smaller energy countershocks budgeted to provide ICD therapy to patients with less severe heart conditions.

25 Dual Battery Configuration

Current ICDs utilize a single battery system to provide all of the energy storage requirements for the device. Unfortunately, the ideal voltage requirements for the monitoring and capacitor-discharge functions of an ICD are almost opposites. For the monitoring function, it
30 is desirable to use the lowest possible voltage that the circuits can operate reliably with in order to conserve energy. This is typically on the order of 1.5 to 3.0 Volts. On the other hand, the output circuit works most

efficiently with the highest possible voltages, including up to 800 Volts. The single battery system of current ICDs is typically comprised of two lithium vanadium pentoxide cells in series that produce about have a battery output voltage (V_b) of about 6 Volts. This voltage V_b is not ideal
5 for either the monitoring or capacitor-discharge functions.

In the preferred embodiment of the present invention, two separate battery systems are used to provide the energy storage requirements of the ICD, one having optimized characteristics for the monitoring functions and one having optimized characteristics for the capacitor-discharge
10 functions. The preferred battery system is a conventional pacemaker power source for the monitoring functions, such as a lithium iodide battery, that is optimized for long life at low current levels. The preferred battery system for the capacitor-discharge function is a conventional ICD battery, such as a lithium vandium pentoxide battery, that is optimized for
15 high current drain capability and low self-discharge for long storage life with few discharges. Due to an excess of low current level in the conventional ICD battery used for the capacitor-discharge function, this battery can also power any pacing functions of the device without affecting its operational requirements to perform the capacitor charging function.
20 By optimizing the two separate battery systems, the overall charge density of each battery can be increased and, hence, the combined volume of both battery systems can be decreased when compared to the single battery system found in the prior art.

Fig. 16 illustrates a block diagram of the preferred embodiment of
25 the dual battery system 130. A battery 132 of appropriate voltage and minimum physical size connects to and powers a monitoring circuit 134 only. Another battery 136 of appropriate voltage and minimum physical size connects to and powers the capacitor-discharge output circuit 138 only. The monitoring circuit 134 and the capacitor-discharge output circuit 138
30 each connect to electrodes 140 positioned near or in the heart 142. The monitoring circuit 134 also connects to and triggers the capacitor-discharge output circuit 138 in the event an arrhythmia is detected. The battery

systems 132 and 136 are optimally size electrically and physically to provide for the most efficient operation in the smallest displacement volume.

Fig. 17 illustrates a dual battery system 150 for an ICD where the
5 batteries are rechargeable. A battery 152 of appropriate voltage and minimum physical size connects to and powers a monitoring circuit 154 only. Another battery 160, which is rechargeable and of appropriate voltage and minimum physical size connects to and powers the capacitor-discharge output circuit 162 only. Charging of the battery 160 occurs by a
10 radio frequency link between an external charger circuit 168 and an implanted recharge circuit 170. A coil 172 connects with the external charger circuit 168 and transmits RF energy from the coil 172 through the epidermis 176 where it is received by the implanted coil 174. The coil 174 supplies RF energy to the recharge circuit 170 so that the battery 160 may be
15 charged. The dual battery system 150 operates and is sized in a manner similar to the dual battery system 130. In the dual battery system 150, the ICD has a finite and predictable monitoring life based upon the capacity of the primary pacing battery 152, and an infinite life for the output power surface battery 160 based on a theoretically perfect secondary rechargeable
20 battery. Optionally, the battery 152 which powers the monitoring circuit 154 could also be rechargeable and would include another similar RF charging link as used for rechargeable battery 160.

Prophylactic Battery Budget

25 Little effort has been expended in developing ICDs for people having mildly abnormal cardiac conditions. Virtually all prior-art effort has gone into systems designed for people with severely abnormal hearts, and hence, have been for lifesaving intervention in crisis situations. Such systems, for a substantial number of reasons, are unsuited for use by
30 patients whose need is for less severe treatment, and for protective intervention at most.

One factor, for example, relates to the criteria embodied in the

system that determine when a shock should be administered. Although substantial progress is being made in devising and developing more accurate methods for identifying tachycardias and fibrillation, uncertainties remain. Hence it is necessary to provide the safety margin
5 discussed above in order to compensate for a range of uncertainty in relation to the appropriateness of shock delivery. When the aim is lifesaving, one chooses a criterion that leads to certain numbers of "false positives," or shocks delivered when not appropriate. A false-positive shock administration is painful and disconcerting to the patient, and
10 potentially hazardous as well, but, in a lifesaving situation, it is preferred to overlooking a true crisis.

Other factors involve the number of shocks that the system must be designed to be able to deliver during its implanted life, and the energy of these delivered shocks. As previously discussed, it has been customary in
15 the prior art to design for 400 countershocks, each having an energy in the range from 30 to 40 joules. As has been demonstrated, both of these factors are directly coupled to the physical size of the system, because of the dominance of the primary battery and the discharge capacitor in determining the physical volume of the system package. Size, in turn,
20 affects possible implantation sites, with a large system requiring implantation in the relatively spacious abdominal cavity, a limiting factor as will be shown below. Not surprisingly, the larger and more powerful systems are also more costly, and this too, limits their utility in prophylactic applications.

25 The prophylactic embodiment of the present invention relates to the concept of a prophylactic ICD with the potential to benefit a large number of patients who now lack the opportunity to be served in a practical way by existing ICD systems. In a prophylactic ICD system, the battery is budgeted to be capable of delivering 200 or fewer countershocks,
30 with each countershock in the range from 10 to 25 joules as a maximum, for a total energy stored by the prophylactic ICD system of 12,000 joules or less. To further conserve electrical energy, the detection algorithms of the

prophylactic ICD are biased to avoid the delivery of false-positive countershocks. Because of the combined factors of fewer countershocks and less energy per countershock, both battery and capacitor can be smaller, resulting in a smaller ICD system of less than about 50cc, thereby
5 allowing for easy pectoral implantation in almost all patients.

In addition to being a more efficient and convenient site than the abdomen, the pectoral site permits use of the housing itself as one electrode in the system for shock delivery. In this case, it augments more conventional cardioverter-defibrillator electrodes associated with a
10 catheter, and will work effectively with such electrodes because current will be routed through the heart muscle in favorable fashion. Because the route is favorable meaning that a substantial fraction of the heart tissue needing electrical treatment is intersected by the current, less energy is required. In further synergy, the catheter may be needed anyway for other
15 functions, such as pacing. The final point in this connection is that ICD electrodes introduced via catheter avoid the need for thoracic surgery, unlike cardiac-patch electrodes, for example.

The battery of the prophylactic ICD embodiment is budgeted so that its requirements and features are not only compatible, but are in fact
20 cooperative and mutually reinforcing. The function of the prophylactic ICD system is to provide modest electrical treatment to a heart that is only mildly impaired, a form of therapy not available on this basis today because prior-art systems are designed for the seriously abnormal heart, and as a result are very poorly suited for protective or preventive
25 applications. The lower energy budget of the battery of the prophylactic ICD also takes advantage of the fact that effective therapy for patient with only mild cardiac dysrhythmia can be provided with less energy because healthier myocardial tissue generally requires less energy for stimulation, i.e., the patient's chronaxie value, d_c , is less than for a patient with severe
30 cardiac disfunction.

The prophylactic ICD system includes a shock-delivery capability amounting to about half as many countershocks as the prior-art system,

with each of the countershock having only one quarter to three quarters as much energy, and with an optimized pulse duration shorter than typical in the prior art, and hence better tuned to the innate heart characteristic time. The smaller size of the less powerful prophylactic ICD system permits very easy implantation of the primary package in the pectoral zone, where its housing can serve advantageously as an electrode for shock delivery, highly compatible with a conventional catheter cardioversion-defibrillation electrode, and thus avoiding thoracic surgery altogether. The necessary battery is relatively small, capable of storing less than 200 total countershock or 12,000 joules, and has a size dictated by the need to charge a small capacitor, less than about 80 μf in a few seconds. As demonstrated using these figures in the optimized battery budget set forth below, the overall size of the prophylactic ICD system can be less than about 40-50cc.

Optimized Battery Budget

Budgeting the E_t for the preferred embodiment of the ICD of the present invention, it will first be noted that the lower maximum E_c of the present invention produces a minimum charging time (t_{\min}) of 8.5 seconds, in contrast to the 12 second minimum in the prior art devices. As used within the present invention, t_{\min} is determined as of the beginning life of the device. It will be recognized, however, that after a period of time the natural decay of the battery system will marginally lengthen t_{\min} .

The use of the improvements to the battery system as previously set forth allows the idle current I_i and the pacing current I_p to be reduced by about half to about 10 μAmps and 3.5 μAmps , respectively, as compared to about 20 μAmps and 7 μAmps in the prior art devices. By reducing the budgeted number of countershock N_p to about 150, rather than 200, it will be seen that the E_t of the preferred embodiment is effectively reduced in half as compared to the prior art devices.

$$E_t = ((I_b * t_c) * N_p) + (I_i * I) + (I_p * I) \quad (\text{Eq. 33})$$

$$\begin{aligned} &= ((8.5 \text{ Amp-sec}) * 150) + (10\mu\text{A} * 5 \text{ years}) + (3.5\mu\text{A} * 5 \\ &\text{years}) \\ &= (0.35 \text{ Amp-hours}) + (0.45 \text{ Amp-hours}) + (0.15 \text{ Amp-} \\ &\text{hours}) \\ 5 \quad &= 1.0 \text{ Amp-hours} \end{aligned}$$

Although the description of the preferred embodiment has been presented, it is contemplated that various changes could be made without deviating from the spirit of the present invention. Accordingly, it is intended that the scope of the present invention be dictated by the
10 appended claims, rather than by the description of the preferred embodiment.

What is claimed is:

CLAIMS

1 1. An implantable cardioverter defibrillator for subcutaneous
2 positioning within a human patient comprising:

3 a sealed housing structure constructed of a biocompatible
4 material and having a displacement volume of less than about 90cc;

5 one or more connector port means, each connector port
6 means disposed in a wall of said housing structure for providing
7 electrical connections between an interior space of said housing
8 structure and a corresponding electrode lead within said human
9 patient;

10 circuit means disposed within said interior space of said
11 housing structure and operably connected to said connector port
12 means for sensing cardiac signals received from one or more of said
13 electrode leads and, in response to the detection of an arrhythmia in
14 said cardiac signals, controlling delivery of one or more high energy
15 electrical cardioversion/defibrillation countershocks of at least 0.5
16 Joules to the myocardium of said human patient;

17 capacitor means disposed within said interior space of said
18 housing structure and operably connected to said circuit means for
19 storing electrical energy to generate said electrical cardioversion/
20 defibrillation countershocks and having an effective capacitance
21 value of less than 120 μ F; and

22 battery means disposed within said interior space of said
23 housing structure and operably connected to said circuit means and
24 said capacitor means for providing electrical energy to said circuit
25 means and said capacitor means,

26 wherein said battery means and said capacitor means are
27 selected such that a maximum electrical charge energy stored by said
28 capacitor means for each of said electrical
29 cardioversion/defibrillation countershocks is less than about 30J
30 and said implantable cardioverter defibrillator is capable of
31 delivering at least five of said electrical cardioversion/defibrillation

32 countershocks in a four minute period.

1 2. The implantable cardioverter defibrillator of claim 1 wherein said
2 circuit means controls the delivery of said electrical cardioversion/
3 defibrillation countershocks such that a pulse duration of a monophasic
4 one of said cardioversion/defibrillation countershocks, or of a first phase
5 of a multiphasic one of said cardioversion/defibrillation countershock is
6 less than about 6 milliseconds.

1 3. The implantable cardioverter defibrillator of claim 1 wherein said
2 battery means is capable of charging said capacitor means to said
3 maximum charge amount in less than about 10 seconds.

1 4. The implantable cardioverter defibrillator of claim 1 wherein said
2 battery means has an estimated life of five years and a total storage capacity
3 of less than about 1.0 Amp-hours.

1 5. The implantable cardioverter defibrillator of claim 1 wherein an
2 optimum capacitance value (C) for said effective capacitance value of said
3 capacitor means is determined by the simultaneous solution of the
4 equations:

$$E_c = 0.5CV_d^2$$

$$C = 0.8d_c/R$$

5
6
7
8
9 where E_c is said maximum charge amount, V_d is a maximum
10 voltage for each of said electrical cardioversion/defibrillation
11 countershocks, d_c is a cardioversion chronaxie value and R is a myocardial
12 tissue resistance value.

1 6. The implantable cardioverter defibrillator of claim 1 wherein said
2 battery means comprises:

3 a first battery means for providing electrical power to said
4 circuit means to monitor said cardiac signals; and

5 a second battery means, separate from said first battery means
6 and having different energy storage characteristics, for providing
7 electrical power to charge said capacitor means to generate said
8 electrical cardioversion/defibrillation countershocks.

near

1 7. The implantable cardioverter defibrillator of claim 1 wherein said
2 displacement value of said housing structure is greater than about 40cc
3 and less than about 80cc.

1 8. The implantable cardioverter defibrillator of claim 1 wherein the
2 total weight of said implantable cardioverter defibrillator is less than about
3 120 grams.

1 9. The implantable cardioverter defibrillator of claim 1 wherein said
2 housing structure has a length to width to thickness ratio of approximately
3 5 to 3 to 1.

1 10. The implantable cardioverter defibrillator of claim 2 wherein the
2 duration of each of said electrical cardioversion/defibrillation
3 countershocks is determined by said circuit means to be the sum of:

4 a first value derived from a first predetermined percentage of
5 an RC time constant, with R being a myocardial tissue resistance
6 value and C being said effective capacitance value of said capacitor
7 means; and

8 a second value derived from a second predetermined
9 percentage of a cardioversion chronaxie, d_c , value.

1- 11. The implantable cardioverter defibrillator of claim 10 wherein said
2 first and second predetermined percentages are between 0.5 and 0.65.

1 12. The implantable cardioverter defibrillator of claim 10 wherein said
2 first value is determined by comparing an output voltage of said electrical
3 cardioversion/defibrillation countershock with said first predetermined
4 percentage and said second value is determined by providing for a fixed
5 time period equal to said second value.

1 13. The implantable cardioverter defibrillator of claim 10 wherein at
2 least one of said electrical cardioversion/defibrillation countershocks is a
3 biphasic pulse having a positive phase and negative phase.

1 14. The implantable cardioverter defibrillator of claim 13 wherein the
2 duration of the positive phase and negative phase are equal and is
3 determined by said circuit means to be the sum of:

4 a first value derived from a first predetermined percentage of
5 an RC time constant, with R being a myocardial tissue resistance
6 value and C being said effective capacitance value of said capacitor
7 means; and

8 a second value derived from a second predetermined
9 percentage of a cardioversion chronaxie, d_c , value.

1 15. An implantable cardioverter defibrillator for subcutaneous
2 positioning within the pectoral region a human patient comprising:

3 a sealed housing structure constructed of a biocompatible
4 material and having a displacement volume of less than about 90cc;

5 one or more connector port means, each connector port
6 means disposed in a wall of said housing structure for providing
7 electrical connections between an interior space of said housing
8 structure and a corresponding electrode lead within said human
9 patient;

10 circuit means disposed within said interior space of said
11 housing structure and operably connected to said connector port
12 means for sensing cardiac signals received from one or more of said

13 electrode leads and, in response to the detection of an arrhythmia in
14 said cardiac signals, controlling delivery of one or more electrical
15 cardioversion/ defibrillation countershocks of at least 0.5 Joules to
16 the myocardium of said human patient;

17 capacitor means disposed within said interior space of said
18 housing structure and operably connected to said circuit means for
19 storing electrical energy to generate said electrical cardioversion/
20 defibrillation countershocks; and

21 battery means disposed within said interior space of said
22 housing structure and operably connected to said circuit means and
23 said capacitor means for providing electrical energy to said circuit
24 means and said capacitor means,

25 wherein said battery means and said capacitor means are
26 selected to maximize a physiologically effective current (I_{pe}) for a
27 maximum electrical charge energy (E_c) stored by said capacitor
28 means.

1 16. The implantable cardioverter defibrillator of claim 15 wherein said
2 physiologically effective current (I_{pe}) is determined by solution of the
3 equation:

4
$$I_{pe} = (I_{ave} * d) / (d_c + d)$$

5 where I_{ave} is an average current of said electrical
6 cardioversion/defibrillation countershocks, d is a duration of said
7 electrical cardioversion/defibrillation countershocks, and d_c is a
8 cardioversion chronaxie value.

1 17. An implantable cardioverter defibrillator for subcutaneous
2 positioning within the pectoral region of a human patient comprising:

3 a sealed housing structure constructed of a biocompatible
4 material and having a displacement volume of less than about 90cc
5 and including one or more connector ports disposed in a wall of
6 said structure for providing electrical connections between an

interior space of said structure and electrode leads in said patient;

circuit means within said interior space for sensing cardiac signals received from said electrode leads and, in response to the detection of an arrhythmia in said cardiac signals, controlling delivery of one or more electrical cardioversion/defibrillation countershocks of at least 0.5 Joules to said patient;

capacitor means within said interior space for storing electrical energy to generate said electrical cardioversion/defibrillation countershocks and having an effective capacitance of less than about 120 μ F; and

battery means within said interior space for providing electrical energy to said circuit means and said capacitor means and capable of charging said capacitor means in less than about 10 seconds to a maximum electrical charge energy of less than about 30 Joules.

18. An implantable cardioverter defibrillator for subcutaneous positioning within the pectoral region of a human patient having electrical energy storage requirements selected so as to treat mild cardiac dysrhythmia conditions comprising:

a sealed housing structure constructed of a biocompatible material and having a displacement volume of less than about 50cc and including one or more connector ports disposed in a wall of said structure for providing electrical connections between an interior space of said structure and electrode leads in said patient;

circuit means within said interior space for sensing cardiac signals received from said electrode leads and, in response to the detection of an arrhythmia in said cardiac signals, controlling delivery of one or more electrical cardioversion/defibrillation countershocks of at least 0.5 Joules to said patient;

capacitor means within said interior space for storing electrical energy to generate said electrical

17 cardioversion/defibrillation countershocks and having an effective
18 capacitance of less than about 80 μ F; and

19 battery means within said interior space for providing
20 electrical energy to said circuit means and said capacitor means and
21 capable of charging said capacitor means in less than about 10
22 seconds to a maximum electrical charge energy of less than about 25
23 Joules,

24 wherein the total amount of electrical energy stored by said
25 battery means is less than 12,000 Joules and the budgeted number of
26 electrical cardioversion/defibrillation countershocks is less than
27 about 200.

1/7

Fig. 1




Fig. 3





Fig. 2



2/7




Fig. 5




Fig. 4

SUBSTITUTE SHEET

3/7




Fig. 6

Fig. 7







Fig. 8



4/7



Fig. 9**Fig. 10**

	CAPACITOR	VOLTS	Ec	Edel	Ipe	Ipec
PRESENT DEVICE	85 μ F	750	26J	2533J	5.67A	7.32 A
PRIOR ART	140 μ F	750	39.4J	34.0J	6.79A	6.79 A



Fig. 11

SUBSTITUTE SHEET



5/7

Fig.12**Fig.13**

6/7

Fig.14**Fig.15**

7/7

Fig. 16**Fig. 17**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 A61N1/39

II. FIELDS SEARCHEDMinimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5

A61N

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched⁸**III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹**

Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0 023 134 (MEDTRONIC) 28 January 1981 see page 7, line 34 - page 8, line 6 ---	1,16,18
A,P	EP,A,0 437 104 (TELECTRONICS) 17 July 1991 see page 10, column 17, line 14 - page 10, column 18, line 36 ---	1,2
A	I.E.E.E. ENGINEERING IN MEDICINE & BIOLOGY vol. 9, no. 2, June 1990, NEW YORK, US pages 19 - 24 PAUL TROUP 'Early development of defibrillation devices' ---	1
A	FR,A,2 528 708 (MIROWSKI) 23 December 1983 see page 12, line 16 - page 14, line 1 ---	1
	--- -/--	

^{*} Special categories of cited documents: ¹⁰^{"A"} document defining the general state of the art which is not considered to be of particular relevance^{"E"} earlier document but published on or after the international filing date^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)^{"O"} document referring to an oral disclosure, use, exhibition or other means^{"P"} document published prior to the international filing date but later than the priority date claimed^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.^{"A"} document member of the same patent family**IV. CERTIFICATION**

Date of the Actual Completion of the International Search

24 JUNE 1993

Date of Mailing of this International Search Report

09-07-1993

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

LEMERCIER D.L.L.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	WO,A,8 901 802 (TELECTRONICS) 9 March 1989 see page 12, line 25 - page 13, line 28 ----	1,2
A	DD,A,286 108 (WIGAND) 17 January 1991 see the whole document -----	5,10,14, 16

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9303249
SA 72793

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

24/06/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0023134	28-01-81	AU-B- 538816	30-08-84
		AU-A- 6066680	22-01-81
		CA-A- 1160296	10-01-84
		JP-C- 1601505	18-02-91
		JP-B- 2026993	13-06-90
		JP-A- 56018880	23-02-81
		US-A- 4375817	08-03-83
		US-A- 4403614	13-09-83
EP-A-0437104	17-07-91	None	
FR-A-2528708	23-12-83	US-A- 4559946	24-12-85
		AU-B- 558515	29-01-87
		AU-A- 1574383	22-12-83
		CA-A- 1210819	02-09-86
		DE-A, C 3321695	05-01-84
		GB-A, B 2122093	11-01-84
		JP-C- 1405397	09-10-87
		JP-A- 59057669	03-04-84
		JP-B- 62015234	06-04-87
		NL-A- 8302182	16-01-84
WO-A-8901802	09-03-89	AU-B- 612187	04-07-91
		AU-A- 2380288	31-03-89
		EP-A- 0331697	13-09-89
		US-A- 5191884	09-03-93
DD-A-286108		None	